Your browser (Internet Explorer 7 or lower) is out of date. It has known security flaws and may not display all features of this and other websites. Learn how to update your browser.

X

Navigate / search

Cutting-Edge Basic Research Awards (CEBRA) (R21)

Key Dates: 
  • Posted Date January 8, 2015
  • Open Date (Earliest Submission Date) July 20, 2015
  • Letter of Intent Due Date(s) Not Applicable
  • Application Due Date(s) August 20, 2015; December 18, 2015; August 19, 2016; December 20, 2016; August 18, 2017; and December 20, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • AIDS Application Due Date(s) August 20, 2015; December 18, 2015; August 19, 2016; December 20, 2016; August 18, 2017; and December 20, 2017, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • Scientific Merit Review November 2015; March 2016; November 2016; March 2017; November 2017; and March 2018
  • Advisory Council Review January 2016, May 2016, January 2017, May 2017, January 2018 and May 2018
  • Earliest Start Date April 1, 2016; July 1, 2016; April 1, 2017; July 1, 2017; April 1, 2018 and July 1, 2018
Purpose: 

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to drug abuse and addiction and how to prevent and treat them. It supports research that is high-risk and potentially high-impact that is underrepresented or not included in NIDA's current portfolio. The proposed research should: (1) test a highly novel and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would have a substantial impact on current thinking; and/or (2) develop or adapt innovative techniques or methods for addiction research, or that have promising future applicability to drug abuse research.

Expiration Date: 
Thursday, December 21, 2017
Announcement Number: 
PAR-15-079